Search

Displaying results 1871 - 1880 of 2954 in total
  1. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

  2. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189165] The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis

  3. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].

  4. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

  5. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    FDA approved on December 14, 2012.

  6. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … [L43747] On December 12, 2025, the FDA expanded niraparib and abiraterone acetate (AKEEGA) with prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer

  7. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year.

  8. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    FDA-approved therapy for this condition. … In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

  9. Drug

    N-acetyl-beta-neuraminic acid

    go.drugbank.com/drugs/DB04265
    Experimental

    (From Dorland, 28th ed, p1518)

  10. Drug

    Dextromoramide

    go.drugbank.com/drugs/DB01529
    ExperimentalIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)